Tharimmune to Present at the Microcap Conference 2025
-
Ireland pip Australia 33-31 in Nations Championship nailbiter
-
Ireland edge Australia 33-31 in Nations Championship nailbiter
-
Antonelli edges Hamilton in sprint to extend title lead
-
Mali hit by new wave of coordinated rebel attacks
-
Rennie 'relief' as All Blacks tenure begins with narrow win over France
-
Hosts Canada, Mexico and USA thrive in their World Cup
-
Europe's baked rice bowl seeks escape from drought
-
Japan beat Italy 27-10 in Nations Championship opener
-
Ukraine says still fighting for eastern stronghold
-
Struggling German auto supplier Continental to sell unit
-
Mali hit by new wave of coordinated attacks
-
Pope urges Europe to protect migrants in visit to island frontier
-
New Zealand edge France 34-32 in thriller to open Nations Championship
-
Mass protests in Germany as far-right AfD meets
-
Pope defends migrants at Mediterranean island frontier
-
France face Philly furnace as World Cup last 16 gets under way
-
Pope to defend migrants at Mediterranean island frontier
-
Australia goalkeepers were in dark about World Cup shootout switch
-
US turns 250 as Trump warns of 'attack' on American identity
-
Billboards, cologne and flowers: Turkish capital gets NATO makeover
-
Feels like 'victory': Cape Verde celebrates heroic World Cup defeat
-
Trump says American identity under 'renewed attack' as US turns 250
-
Haaland's stetson, Cape Verde's pride: World Cup last-32 moments
-
World Cup serves up Wimbledon dilemma: football or tennis?
-
Colombia overcome Ghana to reach World Cup last-16
-
Huge crowds gather as Khamenei funeral ceremonies begin in Iran
-
Cape Verde show anything is possible at World Cup with 'big hearts'
-
Trump set for Mount Rushmore address as US turns 250
-
Huge crowds gather as Khamenei funeral ceremonies open in Iran
-
New species of ghost shark may have been found in Costa Rica
-
Mass protests expected as German far-right AfD meets
-
Argentina advance after Cape Verde World Cup scare, Egypt through
-
Argentina survive Cape Verde scare to reach World Cup last 16
-
Huge crowds expected as Khamenei funeral ceremonies open in Iran
-
England v Mexico World Cup game kickoff time unchanged: FIFA
-
Swift and Kelce marry as global stars swarm 'royal wedding'
-
McDonald's, bus station convert into Venezuela quake clinics
-
Hurdles record-breaker Tharp says 'sky's the limit'
-
'Super typhoon' Bavi heads for US Pacific islands
-
Salah says 'had to do it' after coolest of penalties in World Cup win
-
England seek end to Australia agony in Women's World Cup final
-
Australia's Popovic on defensive as gamble fails in World Cup exit
-
President-elect Fujimori hails 'new chapter' for Peru
-
Maiden ton for Udara as Sri Lanka pile on the runs in 2nd Test
-
Global celebrities pay court at Swift, Kelce "royal wedding"
-
Norway pin hopes on Haaland against Brazil in World Cup last 16
-
Dangerous heat wave roasts America's big birthday party
-
Egypt down Australia to reach World Cup last 16, Cape Verde face Messi
-
Egypt edge Australia on penalties to reach World Cup last 16
-
Families demand help with recovering Venezuela's quake victims
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
